Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1437554

	registered interest
	date	02/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has to make anti-viral covid-19 medication available to elderly people who have tested positive for that disease.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	133220
	answer	answer is ministerial correction date of answer 07/03/2022 answer text <p>1.3 million of the highest risk patients whose immune systems mean they are at higher risk of progression to severe disease, hospital admission or death can receive antivirals directly in England via COVID Medicines Delivery Units.</p><p>Elderly people are eligible for the antiviral molnupiravir through the PANORAMIC study run by the University of Oxford. This study is open to individuals in the United Kingdom who have received a positive polymerase chain reaction test, are aged 50 years old and over or are aged 18 to 49 years old with an underlying medical condition which can increase the risk of developing severe COVID-19. We are awaiting outcomes from the PANORAMIC study before confirming plans to expand the eligible cohort.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 07/03/2022 17:20:20 answering member 4447 label Biography information for Maggie Throup
	tabling member	4471 label Biography information for Rachael Maskell

1504898

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will provide a list of members of the Rapid C-19 Oversight Group.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	47667
	answer	answer is ministerial correction date of answer 22/09/2022 answer text <p>A list of the membership of the RAPID C-19 is attached.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 47568 question first answered 22/09/2022 15:26:16 answering member 4320 label Biography information for Robert Jenrick attachment 1 file name RAPID-C19-oversight-group-membership.docx title RAPID C-19 oversight group membership
	tabling member	4769 label Biography information for Daisy Cooper

1505108

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the (a) size and (b) membership of the RAPID C-19 Oversight Group.
	tabling member constituency	Brentford and Isleworth
	tabling member printed	Ruth Cadbury
	uin	47568
	answer	answer is ministerial correction date of answer 22/09/2022 answer text <p>A list of the membership of the RAPID C-19 is attached.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 47667 question first answered 22/09/2022 15:26:16 answering member 4320 label Biography information for Robert Jenrick attachment 1 file name RAPID-C19-oversight-group-membership.docx title RAPID C-19 oversight group membership
	tabling member	4389 label Biography information for Ruth Cadbury

1463834

	registered interest
	date	17/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the efficacy of existing COVID-19 antiviral treatments for eligible patients in reducing rates of hospitalisation and death.
	tabling member printed	Lord Mendelsohn
	uin	HL309
	answer	answer is ministerial correction date of answer 27/05/2022 answer text <p>A range of treatment options are available to non-hospitalised patients at higher risk from COVID-19 to reduce severe disease, hospitalisation and death. These treatments are available through COVID Medicines Delivery Units and include the oral antivirals nirmatrelvir+ritonavir (Paxlovid), molnupiravir and the infusion antiviral remdesivir.</p><p>Evidence from clinical trials suggests these treatments can reduce the risk of hospitalisation. For molnupiravir, interim results found a 50% reduction in the relative risk of hospitalisation or death compared to placebo. However, updated results indicate molnupiravir reduces the relative risk of hospitalisation or death by 30% compared to placebo. Pfizer’s final analysis on the clinical trials of nirmatrelvir+ritonavir showed an 88% reduction in hospitalisation or death compared to a placebo within five days of symptom onset. No assessment of how these treatments have impacted rates of hospitalisation since December has been made.</p><p>Both molnupiravir and nirmatrelvir+ritonavir are being trialled as part of the PANORAMIC national study. Results for molnupiravir are expected in summer 2022. Recruitment for the nirmatrelvir + ritonavir opened on 11 April 2022. The study will collect further data on how these treatments work in a United Kingdom context where the majority of the population is vaccinated. It will also provide baseline information on how antivirals could be used for best clinical effect in combination with antibodies or other antiviral drugs as they become available. A 2021 trial showed that among non-hospitalised patients at high risk for COVID-19 progression, a three-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalisation or death than placebo.</p> answering member printed Lord Kamall question first answered 27/05/2022 10:43:45 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1187367

	registered interest
	date	23/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the drugs being used in other countries to treat patients with COVID-19 successfully; and what progress has been made towards developing a vaccine.
	tabling member printed	Lord Roberts of Llandudno
	uin	HL2829
	answer	answer is ministerial correction date of answer 07/04/2020 answer text <p>Although several potential drugs for COVID-19 are being trialled around the world, few results have been reported yet, and we do not know if any could help save people who are already seriously ill when diagnosed.</p><p>The World Health Organization (WHO) along with several countries in Europe, including the United Kingdom, are coordinating an international trial of the most promising drugs which include the long-used antimalarial drugs chloroquine and hydroxychloroquine, a new antiviral drug called remdesivir and a combination of two HIV drugs called lopinavir and ritonavir. The HIV drugs will also be tested in combination with an antiviral called interferon beta.</p><p>The trial will focus on whether any of these drugs reduce mortality or the time patients are in hospital and whether patients receiving drugs require ventilation or an intensive care unit.</p><p>On 3 April, the Government also announcement that the world’s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment.</p><p>Scientific and medical advisers are already developing a new vaccine against the COVID-19, as they initiated vaccine development as soon as the genetic sequence of the novel coronavirus was released.</p> answering member printed Lord Bethell question first answered 07/04/2020 11:43:09 answering member 4708 label Biography information for Lord Bethell
	tabling member	3691 label Biography information for Lord Roberts of Llandudno

1454243

	registered interest
	date	24/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many COVID-19 patients are currently in hospital; whether those patients are being given antiviral treatments to aid their recovery; and if so, what is the average length of time it takes patients receiving such treatments to be cured.
	tabling member printed	Baroness Rawlings
	uin	HL7339
	answer	answer is ministerial correction date of answer 30/03/2022 answer text <p>As of 28 March 2022, the number of patients currently in hospital with COVID-19 is 17,685. A range of treatments are available to these patients, including antivirals. Eligible patients admitted to hospital for reasons not related to COVID-19 and subsequently test positive are able to access nirmatrelvir + ritonavir (Paxlovid), an oral antiviral treatment or remdesivir, an intravenous antiviral. For patients whose immune system means they are at higher risk of COVID-19, the antiviral treatments molnupiravir, nirmatrelvir + ritonavir and remdesivir are available in the community to reduce the risk of hospitalisation and death.</p><p> </p><p>Approximately 120,000 treatments have been provided in England, of which 53,000 were antivirals administered to hospitalised patients. The data requested on the average time for patients receiving antivirals to be cured is not held centrally.</p> answering member printed Lord Kamall question first answered 30/03/2022 11:00:09 answering member 4909 label Biography information for Lord Kamall
	tabling member	3278 label Biography information for Baroness Rawlings

1469939

	registered interest
	date	13/06/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many patients in the UK have been treated by covid-19 medicines delivery units.
	tabling member constituency	Streatham
	tabling member printed	Bell Ribeiro-Addy
	uin	17129
	answer	answer is ministerial correction date of answer 21/06/2022 answer text <p>As of 5 June 2022, approximately 47,000 non-hospitalised patients in England have been treated by COVID Medicines Delivery Units (CMDUs). CMDUs are operational in England, with equivalent services in Scotland, Wales and Northern Ireland. As of 5 June, approximately 62,000 non-hospitalised patients in the United Kingdom have received COVID-19 treatments through these services.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 21/06/2022 10:58:28 answering member 4447 label Biography information for Maggie Throup previous answer version 6887 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	4764 label Biography information for Bell Ribeiro-Addy

1569102

	registered interest
	date	20/01/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the creation by NHS England of a national expert working group (EWG), why it has only met twice; and whether it still has an active role in supporting the development of a national clinical policy.
	tabling member printed	Lord Mendelsohn
	uin	HL4942
	answer	answer is ministerial correction date of answer 07/02/2023 answer text <p>As part of pandemic-specific arrangements, NHS England was asked to utilise its national clinical policy making expertise to lead on the development of United Kingdom-wide clinical access policy drafts enabling access to evidence-based COVID treatments. These draft policies are then considered and approved by the UK Chief Medical Officers ahead of publication, to guide the decisions of treating clinicians, and supporting medicines supply arrangements.</p><p> </p><p>NHS England has been supported in this role by a range of clinical and academic experts, including representatives from the devolved administrations in Northern Ireland, Scotland and Wales, who meet as part of Expert Working Group arrangements. There is not a standing or single expert working group but rather a series of clinical policy-specific expert working groups that have been established and that meet, as required, with clinical expertise specific to the medicine or medicines being considered. For example, an expert working group was established specific to Evusheld as pre-exposure prophylaxis, which met twice.</p><p> </p><p>Through this expert working group approach, clinicians and academics have provided advice which has helped clinical policy makers to better understand the supporting clinical trial information, to identify any important contraindications or drug to drug interactions that need to be considered, and to understand how best to place a potential new medicine option alongside current treatment choices. This has provided NHS England with both clinical subject matter and specialty expertise and a valuable ‘front line’ perspective in developing access policy proposals.</p> answering member printed Lord Markham question first answered 07/02/2023 14:02:42 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1463750

	registered interest
	date	17/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many doses of covid-19 antivirals have been administered to (a) immunocompromised individuals and (b) people of working age after contracting covid-19 during the period of 17 March 2022 to 17 May 2022.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	3628
	answer	answer is ministerial correction date of answer 24/05/2022 answer text <p>Between 17 March and 17 May 2022, 15,793 courses of antiviral treatments were provided to eligible individuals in England, who had tested positive for COVID-19. Of these patients, 10,256 individuals were aged 17 to 69 years old. However, the information requested on those who are immunocompromised is not held centrally.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 24/05/2022 13:40:08 answering member 4447 label Biography information for Maggie Throup
	tabling member	4398 label Biography information for Chris Green

1464158

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many covid-19 antiviral courses have been administered to patients in a hospital setting since those courses became available.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	4604
	answer	answer is ministerial correction date of answer 26/05/2022 answer text <p>Between 5 July 2020 and 15 May 2022, 635 courses of Paxlovid and 55,523 courses of remdesivir were administered to hospitalised patients and those with hospital-onset COVID-19 in England.</p><p> </p><p> </p> answering member constituency Erewash answering member printed Maggie Throup question first answered 26/05/2022 14:57:06 answering member 4447 label Biography information for Maggie Throup
	tabling member	4398 label Biography information for Chris Green